Immunosuppressive therapy for heart failure: A guide to patient selection

American Journal of Cardiovascular Drugs

Volumn 3, Issue 5, 2003, Pages 321-324

  Nowalany Kozielska, Ewa ^a   Wojnicz, Romuald ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOGLOBULIN; PREDNISONE; SPIRONOLACTONE;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE COURSE; DOSE RESPONSE; HEALTH STATUS; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE INJURY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; ISCHEMIC HEART DISEASE; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; MORTALITY; MYOCARDITIS; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS;

GUIDELINES; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS;

EID: 0242636321     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303050-00003     Document Type: Article

References (33)

1. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999; 83 (2A): 1A-38A
2. Sharpe N, Doughty R. Epidemiology of heart failure and ventricular dysfunction. Lancet 1998; 352: 3-7
3. Mann DL. Mechanisms and models in heart failure: a combinatory approach. Circulation 1999; 100: 999-1008
4. Devaux B, Scholz D, Hirche A, et al. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997; 19: 470-9
5. Cella F, Michels VV. The autoimmune basis of dilated cardiomyopathy. Ann Med 1995; 27: 169-73
6. Hasper D, Hummel M. Kleber FX, et al. Systemic inflammation in patients with heart failure. Eur Heart J 1998; 19: 761-5
7. Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 376-82
8. Klappacher G, Mehrabi M, Franzen P, et al. Endomyocardial HLA expression is increased to the same extent in idiopathic and secondary dilated cardiomyopathy. Immunol Lett 1994; 41: 59-66
9. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure: Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J 2001; 22: 1527-60
10. Chow LC, Dittrich HC, Shabetai R. Endomyocardial biopsy in patients with unexplained heart failure. Ann Intern Med 1988; 109: 535-9
11. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987; 18: 619-24
12. Chow LH, Radio SJ, Sears TD, et al. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 1989; 14: 915-20
13. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995; 333: 269-75
14. Kuhl U, Noutsias M, Schyltheiss HP. Immunohistochemistry in dilated cardiomyopathy. Eur Heart J 1995; 16: 100-6
15. Nousias M, Seeberg B, Schultheiss HP, et al. Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 1999; 99: 2124-31
16. Maisch B, Schonian U, Hengstenberg C, et al. Immunosuppressive treatment in autoreactive myocarditis -results from a controlled trial. Postgrad Med J 1994; 70: 29-34
17. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001; 104: 39-45
18. Kolbeck PC, Steenbergen C, Wolfe JA, et al. The correlation of mononuclear cell phenotype in endomyocardial biopsies with clinical history and cardiac dysfunction. Am J Clin Pathol 1989; 9: 37-44
19. Khl U, Seeberg B, Schultheiss HP, et al. Immunohistological characterization of infiltrating lymphocytes in biopsies of patients with clinically suspected dilated cardiomyopathy. Eur Heart J 1994; 15: 62-7
20. Badorff C, Noutsias M, Kuhl U, et al. Cell-mediated cytotoxicity in hearts with dilated cardiomyopathy: correlation with interstitial fibrosis and foci of activated T lymphocytes. J Am Coll Cardiol 1997; 29: 429-34
21. Wojnicz R, Nowalany-Kozielska E, Wodniecki J, et al. Immunohistological diagnosis of myocarditis: potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury. Eur Heart J 1998; 19: 1564-72
22. McDouall RM, Yacoub M, Rose ML. Isolation, culture, and characterisation of MHC class II-positive microvascular endothelial cells from the human heart. Microvasc Res 1996; 51: 137-52
23. Tanio JW, Basu CB, Albelda SM, et al. Differential expression of the cell adhesion molecules ICAM-1, VCAM-1, and E-selectin in normal and posttransplantation myocardium: cell adhesion molecule expression in human cardiac allografts. Circulation 1994; 89: 1760-8
24. Ansari AA, Wang YC, Danner DJ, et al. Abnormal expression of histocompatibility and mitochondrial antigens by cardiac tissue from patients with myocarditis and dilated cardiomyopathy. Am J Pathol 1991; 139: 337-54
25. 2-adrenoceptor with positive chronotropic effect. Circulation 1994; 89: 2760-7
26. Rose NR, Herskowitz A, Neumann DA. Autoimmunity in myocarditis: models and mechanisms. Clin Immunol Immunopathol 1993; 68: 95-9
27. Parrillo JE, Cunnion RE, Epstein SE, et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989; 321: 1061-8
28. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254-9
29. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220-5
30. O'Connell JB. The role of myocarditis in end-stage dilated cardiomyopathy. Tex Heart Inst J 1987; 14: 268-75
31. Figulla HR, Rahlf G, Nieger M, et al. Spontaneous hemodynamic improvement of stabilization and associated biopsy findings in patients with congestive cardiomyopathy. Circulation 1985; 71: 1095-104
32. Liu P, Mason JW. Advances in the understanding of myocarditis. Circulation 2001; 104: 1076-82
33. Grogan M, Redfield MM, Bailey KR, et al. Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1995; 26: 80-4